Innoviva earnings release, August 5, 2026

Innoviva, Inc. (INVA) · Form 8-K, Item 2.02 · Filed · SEC filing

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth

Royalties portfolio generated $59.8 million in second quarter revenue

Launch of wholly-owned Strategic Healthcare Asset, Nortiva Bio, focused on novel extended-release drug delivery technology

BURLINGAME, Calif. – Aug 5, 2026 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements.

“Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent commercial momentum at IST, which achieved 46% year-over-year net product sales growth, including 26% growth in U.S. sales. We remain on track to achieve at least $150 million in IST U.S. net product sales in 2026, reflecting the differentiation of our marketed critical care and infectious disease portfolio and robust execution,” said Pavel Raifeld, Chief

Executive Officer of Innoviva.

“Recently, we also advanced several growth opportunities. This quarter, we announced a commercialization and licensing agreement with Dr. Reddy’s Laboratories, expanding access to our top-performing antibiotic, XACDURO, in emerging markets. Additionally, we launched Nortiva Bio, a novel platform for long-acting oral medicine delivery, with large upside potential.”

“Overall, we have been pleased with progress across our healthcare asset portfolio, despite market volatility. Our continued activity under the share repurchase program reflects our sustained conviction in the long-term prospects of our diversified business model — one that combines durable cash generation, strong operating revenue growth, and value creation in high-potential strategic opportunities.”

Financial Highlights for the Second Quarter of 2026

Key Business and R&D Highlights

- 2 -

About Innoviva

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva

Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®

/BREO®

ELLIPTA® and ANORO®

ELLIPTA®. Innoviva’s critical care and infectious disease assets under the IST platform include GIAPREZA®

(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock, XACDURO®

(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of

Acinetobacter baumannii-calcoaceticus, XERAVA®

(eravacycline) for the treatment of complicated intra-abdominal infections in adults, ZEVTERA (ceftobiprole), an advanced-generation cephalosporin antibiotic licensed from Basilea Pharmaceutica International Ltd, Allschwil, and NUZOLVENCE®

(zoliflodacin), approved by the FDA for the oral treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years of age and older weighing at least 35 kg. For more information about Innoviva, go to www.inva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaspecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2026 – (unaudited)Three Months Ended June 30, – 2025Three Months Ended June 30, – 2025 – (unaudited)Six Months Ended June 30, – 2026Six Months Ended June 30, – 2026 – (unaudited)Six Months Ended June 30, – 2025Six Months Ended June 30, – 2025 – (unaudited)
Revenue:Royalty revenue, net (1)56,33463,880111,501121,687
Revenue:Net product sales51,77135,49393,14265,772
Revenue:License and other revenue11,48691012,9421,456
Revenue:Total revenue119,591100,283217,585188,915
Revenue:Cost of products sold (inclusive of amortization of inventory fair value adjustments)22,34910,59037,95619,432
Revenue:Amortization of acquired intangible assets6,6266,54713,18013,022
Revenue:Gross profit90,61683,146166,449156,461
Operating expenses:Selling, general and administrative34,57126,41267,00953,903
Operating expenses:Research and development5,1907,98310,43112,379
Operating expenses:Total operating expenses39,76134,39577,44066,282
Operating expenses:Income from operations50,85548,75189,00990,179
Operating expenses:Changes in fair values of equity method investments, net-131,83413,08225,816-467
Operating expenses:Changes in fair values of equity and long-term investments, net-29,15311,2804,422-54,019
Operating expenses:Interest and dividend income7,5994,92518,5869,463
Operating expenses:Interest expense-5,472-4,663-10,909-9,374
Operating expenses:Other expense, net-15-777-381-1,773
Operating expenses:Income (loss) before income taxes-108,02072,598126,54334,009
Operating expenses:Income tax benefit (expense)24,600-8,910-23,368-16,905
Operating expenses:Net income (loss)-83,42063,688103,17517,104
Net income (loss) per share:Basic-1.141.011.40.27
Net income (loss) per share:Diluted-1.140.771.250.24
Shares used to compute net income (loss) per share:Basic73,42162,86573,78962,787
Shares used to compute net income (loss) per share:Diluted73,42184,45284,52984,342
Shares used to compute net income (loss) per share:(1) Total net revenue is comprised of the following (in thousands):(1) Total net revenue is comprised of the following (in thousands):(1) Total net revenue is comprised of the following (in thousands):(1) Total net revenue is comprised of the following (in thousands):(1) Total net revenue is comprised of the following (in thousands):
Shares used to compute net income (loss) per share:Royalties59,79067,336118,413128,599
Shares used to compute net income (loss) per share:Amortization of capitalized fees-3,456-3,456-6,912-6,912
Shares used to compute net income (loss) per share:Royalty revenue, net56,33463,880111501.0 #121,687

Balance Sheet

June 30, 2026 — (unaudited) (in thousands)

June 30, 2026December 31, 2025
AssetsCash and cash equivalents570,388550,941
AssetsRoyalty and product sale receivables110,61693,317
AssetsInventory38,96839,172
AssetsPrepaid expense and other current assets24,72628,358
AssetsCurrent portion of ISP Fund investments8,66815,727
AssetsProperty and equipment, net2,1331,555
AssetsEquity method and equity and long-term investments660,850598,223
AssetsCapitalized fees49,22656,138
AssetsRight-of-use assets10,37710,929
AssetsGoodwill17,90517,905
AssetsIntangible assets168,976182,156
AssetsOther assets39,89440,744
AssetsTotal assets1,702,7271,635,165
Liabilities and stockholders’ equityOther current liabilities39,43143,808
Liabilities and stockholders’ equityAccrued interest payable1,6181,618
Liabilities and stockholders’ equityDeferred revenue6,0154,270
Liabilities and stockholders’ equityConvertible senior notes, due 2028, net258,454257,731
Liabilities and stockholders’ equityDeferred tax liabilities, net36,73931,793
Liabilities and stockholders’ equityIncome tax payable, long term59,93257,013
Liabilities and stockholders’ equityOther long term liabilities67,27666,091
Liabilities and stockholders’ equityStockholders’ equity1,233,2621,172,841
Liabilities and stockholders’ equityTotal liabilities and stockholders’ equity1,702,7271,635,165

Cash Flow

Six Months Ended June 30, — (unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net cash provided by operating activities87,25492,690
Net cash used in investing activities-18,256-1,552
Net cash provided by (used in) financing activities-49,5511,430
Net change19,44792,568
Cash and cash equivalents at beginning of period550,941304,964
Cash and cash equivalents at end of period570,388397,532
Full release

This press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation

Reform Act of 1995. The words “anticipate”, “expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”, “potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of

RELVAR®

/BREO®

ELLIPTA®, ANORO®

ELLIPTA®, GIAPREZA®,

XERAVA®, XACDURO®, ZEVTERA® and NUZOLVENCE® in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s growth strategy and corporate development... (truncated)NX® platform; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital

- 3 - returns to stockholders; and risks related to the Company’s growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on

Form

10-K for the year ended December 31, 2025 and Quarterly Reports on Form

10-Q, which are on file with the Securities and Exchange

Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

- 4 -

INNOVIVA, INC.

Condensed Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

- 5 -

INNOVIVA, INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

- 6 -

INNOVIVA, INC.

Cash Flows Summary

(in thousands)

(unaudited)

- 7 -

Investors and media contact

Irwin Tendler

Head of Investor Relations

Executive Director, Corporate Development investors.relations@inva.com

- 8 -

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Innoviva earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.